UNITED THERAPEUTICS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $496.06 ($493.22–$501.60, $4.71M total) across 9 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $497.54 ($495.97–$501.58, $4.13M total) across 7 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.39 ($498.45–$505.20, $4.76M total) across 8 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent UTHR coverage spans insider activity and financial news.
In the last 30 days, UTHR insiders filed 237 SEC Form 4 transactions — no purchases and 237 sales ($108.8M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 208 filings. 99% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale by the chairperson suggests potential downside pressure on UTHR.
The sale represents a modest insider divestment that may signal slight downside pressure.
Large insider sell may pressure the stock short term.
The insider sale may signal a modest negative sentiment but the size is small relative to market cap.
Insider sale by the chairperson may signal reduced confidence, potentially pressuring the stock short term.
AlphAI scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $496.06 ($493.22–$501.60, $4.71M total) across 9 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readMAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $497.54 ($495.97–$501.58, $4.13M total) across 7 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.39 ($498.45–$505.20, $4.76M total) across 8 trades on 2026-09-16 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.59 ($499.77–$504.57, $4.77M total) across 6 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $504.12 ($502.15–$506.48, $4.79M total) across 5 trades on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readMesa Nilda sold 228 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $505.87 ($505.79–$505.98, $0.12M total) across 2 trades on 2026-09-14.
1 min readCPI Card Group (PMTS) insiders, including directors and a 10% owner, bought 549,981 shares at $21.50 each on September 14, 2026. The stock has since rebounded to $24.26, with a 65% YTD gain. InvestingPro analysis suggests PMTS is undervalued. Devon Energy (DVN) CEO bought 3,913 shares at $51.07-$51.09, near its 52-week high. Republic Services (RSG) 10% owner bought 580,710 shares at $221.52-$224.11, but InvestingPro deems it overvalued. Chime Financial (CHYM) directors sold 1.16M shares at $32.8
2 min readUnited Therapeutics (UTHR) outlined plans to expand into pulmonary fibrosis, a larger market than its current focus on pulmonary hypertension. Management highlighted an $8B near-term revenue target and a long-term opportunity of $40B-$100B. Key products include nebulized Tyvaso for IPF, with FDA review underway. Shares closed at $502.7, up 1.12%.
3 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $500.82 ($496.74–$508.21, $4.76M total) across 12 trades on 2026-09-11 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $502.35 ($498.44–$508.80, $4.77M total) across 10 trades on 2026-09-10 under a Rule 10b5-1 trading plan.
1 min read